BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 29460266)

  • 1. Increased Levels of Rictor Prevent Mutant Huntingtin-Induced Neuronal Degeneration.
    Creus-Muncunill J; Rué L; Alcalá-Vida R; Badillos-Rodríguez R; Romaní-Aumedes J; Marco S; Alberch J; Perez-Otaño I; Malagelada C; Pérez-Navarro E
    Mol Neurobiol; 2018 Oct; 55(10):7728-7742. PubMed ID: 29460266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
    Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
    Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synaptic RTP801 contributes to motor-learning dysfunction in Huntington's disease.
    Martín-Flores N; Pérez-Sisqués L; Creus-Muncunill J; Masana M; Ginés S; Alberch J; Pérez-Navarro E; Malagelada C
    Cell Death Dis; 2020 Jul; 11(7):569. PubMed ID: 32732871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.
    Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F
    J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTORC2/AKT/HSF1/HuR constitute a feed-forward loop regulating Rictor expression and tumor growth in glioblastoma.
    Holmes B; Benavides-Serrato A; Freeman RS; Landon KA; Bashir T; Nishimura RN; Gera J
    Oncogene; 2018 Feb; 37(6):732-743. PubMed ID: 29059166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
    Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
    Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of mTORC2/RICTOR Impairs Melanoma Hepatic Metastasis.
    Schmidt KM; Dietrich P; Hackl C; Guenzle J; Bronsert P; Wagner C; Fichtner-Feigl S; Schlitt HJ; Geissler EK; Hellerbrand C; Lang SA
    Neoplasia; 2018 Dec; 20(12):1198-1208. PubMed ID: 30404068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of Rictor/mTORC2 in cardiomyocyte differentiation of mouse embryonic stem cells
    Zheng B; Wang J; Tang L; Tan C; Zhao Z; Xiao Y; Ge R; Zhu D
    Int J Biol Sci; 2017; 13(1):110-121. PubMed ID: 28123351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
    Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
    Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
    Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
    Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rictor/mTORC2 pathway in oocytes regulates folliculogenesis, and its inactivation causes premature ovarian failure.
    Chen Z; Kang X; Wang L; Dong H; Wang C; Xiong Z; Zhao W; Jia C; Lin J; Zhang W; Yuan W; Zhong M; Du H; Bai X
    J Biol Chem; 2015 Mar; 290(10):6387-96. PubMed ID: 25564616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective degeneration in YAC mouse models of Huntington disease.
    Van Raamsdonk JM; Warby SC; Hayden MR
    Brain Res Bull; 2007 Apr; 72(2-3):124-31. PubMed ID: 17352936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease.
    Singh BK; Vatsa N; Nelson VK; Kumar V; Kumar SS; Mandal SC; Pal M; Jana NR
    Mol Neurobiol; 2018 Aug; 55(8):6337-6346. PubMed ID: 29294248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells.
    Venugopal SV; Caggia S; Gambrell-Sanders D; Khan SA
    Prostate; 2020 Apr; 80(5):412-423. PubMed ID: 31995655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.
    Morrison Joly M; Hicks DJ; Jones B; Sanchez V; Estrada MV; Young C; Williams M; Rexer BN; Sarbassov dos D; Muller WJ; Brantley-Sieders D; Cook RS
    Cancer Res; 2016 Aug; 76(16):4752-64. PubMed ID: 27197158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased translation as a novel pathogenic mechanism in Huntington's disease.
    Creus-Muncunill J; Badillos-Rodríguez R; Garcia-Forn M; Masana M; Garcia-Díaz Barriga G; Guisado-Corcoll A; Alberch J; Malagelada C; Delgado-García JM; Gruart A; Pérez-Navarro E
    Brain; 2019 Oct; 142(10):3158-3175. PubMed ID: 31365052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
    Ruicci KM; Plantinga P; Pinto N; Khan MI; Stecho W; Dhaliwal SS; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Nichols AC
    Mol Oncol; 2019 Oct; 13(10):2160-2177. PubMed ID: 31393061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex.
    Gkountakos A; Pilotto S; Mafficini A; Vicentini C; Simbolo M; Milella M; Tortora G; Scarpa A; Bria E; Corbo V
    Carcinogenesis; 2018 Jul; 39(8):971-980. PubMed ID: 29955840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of striatal 90-kDa ribosomal S6 kinase (Rsk) is a key factor for motor, synaptic and transcription dysfunction in Huntington's disease.
    Anglada-Huguet M; Giralt A; Rué L; Alberch J; Xifró X
    Biochim Biophys Acta; 2016 Jul; 1862(7):1255-66. PubMed ID: 27063456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease.
    Pfister EL; DiNardo N; Mondo E; Borel F; Conroy F; Fraser C; Gernoux G; Han X; Hu D; Johnson E; Kennington L; Liu P; Reid SJ; Sapp E; Vodicka P; Kuchel T; Morton AJ; Howland D; Moser R; Sena-Esteves M; Gao G; Mueller C; DiFiglia M; Aronin N
    Hum Gene Ther; 2018 Jun; 29(6):663-673. PubMed ID: 29207890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.